Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of CriPec docetaxel monotherapy in platinum-resistant ovarian cancer
NL-OMON50067Phase 2Completed
- Sponsor
- Cristal Therapeutics
- Start
- Sep 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cristal Therapeutics. Primary endpoint: Objective response rate. Started Sep 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON50067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50067.